These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 22193214)

  • 1. A turbulent decade for NSAIDs: update on current concepts of classification, epidemiology, comparative efficacy, and toxicity.
    Conaghan PG
    Rheumatol Int; 2012 Jun; 32(6):1491-502. PubMed ID: 22193214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Review of the cardiovascular safety of COXIBs compared to NSAIDS.
    Moodley I
    Cardiovasc J Afr; 2008; 19(2):102-7. PubMed ID: 18516356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Cardiovascular toxicity of selective COX-2-inhibitors and classical NSAIDs].
    Lange H; Eberhart L
    Anasthesiol Intensivmed Notfallmed Schmerzther; 2007 Jul; 42(7):514-7. PubMed ID: 17661262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclo-oxygenase-2 selective inhibitors and nonsteroidal anti-inflammatory drugs: balancing gastrointestinal and cardiovascular risk.
    Moore RA; Derry S; McQuay HJ
    BMC Musculoskelet Disord; 2007 Aug; 8():73. PubMed ID: 17683540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of non-steroidal anti-inflammatory drugs that elevate cardiovascular risk: an examination of sales and essential medicines lists in low-, middle-, and high-income countries.
    McGettigan P; Henry D
    PLoS Med; 2013; 10(2):e1001388. PubMed ID: 23424288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cardiovascular and gastrointestinal risks associated with selective and non-selective NSAIDs].
    van den Bemt BJ; Benraad HB; Rasker JJ
    Ned Tijdschr Geneeskd; 2007 May; 151(19):1062-7. PubMed ID: 17552414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Practical approaches to minimizing gastrointestinal and cardiovascular safety concerns with COX-2 inhibitors and NSAIDs.
    Scheiman JM; Fendrick AM
    Arthritis Res Ther; 2005; 7 Suppl 4(Suppl 4):S23-9. PubMed ID: 16168078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concomitant use of gastroprotective drugs among elderly NSAID/COX-2 selective inhibitor users: a nationwide register-based study.
    Johnell K; Fastbom J
    Clin Drug Investig; 2008; 28(11):687-95. PubMed ID: 18840011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular safety of non-steroidal anti-inflammatory drugs among healthy individuals.
    Fosbøl EL; Køber L; Torp-Pedersen C; Gislason GH
    Expert Opin Drug Saf; 2010 Nov; 9(6):893-903. PubMed ID: 20569079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Minimizing risks of NSAIDs: cardiovascular, gastrointestinal and renal.
    Davies NM; Reynolds JK; Undeberg MR; Gates BJ; Ohgami Y; Vega-Villa KR
    Expert Rev Neurother; 2006 Nov; 6(11):1643-55. PubMed ID: 17144779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. COX-2 inhibition: what we learned--a controversial update on safety data.
    Katz JA
    Pain Med; 2013 Dec; 14 Suppl 1():S29-34. PubMed ID: 24373107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unmet needs in non-steroidal anti-inflammatory drug-induced upper gastrointestinal diseases.
    Scheiman JM
    Drugs; 2006; 66 Suppl 1():15-21; discussion 29-33. PubMed ID: 16869344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prescription of nonselective NSAIDs, coxibs and gastroprotective agents in the era of rofecoxib withdrawal - a 617,400-patient study.
    Valkhoff VE; van Soest EM; Masclee GM; de Bie S; Mazzaglia G; Molokhia M; Kuipers EJ; Sturkenboom MC
    Aliment Pharmacol Ther; 2012 Oct; 36(8):790-9. PubMed ID: 22928490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-Steroidal anti inflammatory drugs usage in orthopaedics and trauma practice. A guide and review.
    Eyichukwu GO
    Niger J Med; 2010; 19(4):374-81. PubMed ID: 21526623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-inflammatory drugs in the 21st century.
    Rainsford KD
    Subcell Biochem; 2007; 42():3-27. PubMed ID: 17612044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation.
    Chen YF; Jobanputra P; Barton P; Bryan S; Fry-Smith A; Harris G; Taylor RS
    Health Technol Assess; 2008 Apr; 12(11):1-278, iii. PubMed ID: 18405470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular risks of cyclooxygenase inhibition.
    Stacy ZA; Dobesh PP; Trujillo TC
    Pharmacotherapy; 2006 Jul; 26(7):919-38. PubMed ID: 16803424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pain, analgesics, and the cardiovascular system.
    Wehrmacher WH; Messmore HL; Haque W
    Compr Ther; 2006; 32(4):236-9. PubMed ID: 17898429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ischaemic cardiovascular risk and prescription of non-steroidal anti-inflammatory drugs for musculoskeletal complaints.
    Koffeman AR; Valkhoff VE; Jong GW; Warlé-van Herwaarden MF; Bindels PJ; Sturkenboom MC; Luijsterburg PA; Bierma-Zeinstra SM
    Scand J Prim Health Care; 2014 Jun; 32(2):90-8. PubMed ID: 24931511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonsteroidal anti-inflammatory drugs (NSAIDs), cyxlooxygenase-2 selective inhibitors (coxibs) and gastrointestinal harm: review of clinical trials and clinical practice.
    Moore RA; Derry S; Phillips CJ; McQuay HJ
    BMC Musculoskelet Disord; 2006 Oct; 7():79. PubMed ID: 17054784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.